Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Protease-activated-receptor-2 antagonists for treatment of migraine pain

Award Number: R41NS127637
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/15/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2024

Group Awards By:

View Award Description

Protease-activated-receptor-2 antagonists for treatment of migraine pain - PROJECT SUMMARY Migraine affects over 36 million people in the US, particularly those of working age (18-55 years), negatively impacting workplace productivity and presenting an enormous healthcare burden. For almost half of those who suffer from migraine, current treatments fail to provide relief and have limited ability to reverse pain once it has started. The most effective medications either require injection (CGRP antibodies) or are associated with increased cardiovascular risk (triptans). In addition, none of these provide complete relief to most patients. Migraine pain results from aberrant activation of specialized neurons that innervate the meninges, resulting in the release of neurotransmitters that cause local inflammation, and trigger a pain signal to central terminals in the brainstem. This signal is then carried to higher brain centers resulting in the perception of pain, and the continued presence of inflammatory mediators in the periphery perpetuate this painful signal. Protease-activated-receptor-2 (PAR2) is a membrane receptor that is activated by enzymes that are released from immune cells in the meninges, over the course of a migraine attack. Its activation contributes to migraine pain at multiple points: increasing the release of excitatory neurotransmitters; lowering the threshold for activation of pain transmitting neurons; and promoting the synthesis of additional inflammatory mediators. The main site of action of PAR2 is in the peripheral nerve terminals. This is in contrast to the targets of current migraine therapeutics that also play major roles in the central nervous system. We have identified two small molecule inhibitors of PAR2 that reduce migraine-like pain in animals. Significantly, these molecules act without crossing the blood brain barrier (BBB), even when administered after the onset of an attack. In this proposal, we aim to modify the chemical scaffold of our lead compound to improve its potential for oral delivery. We will use a high throughput screen to examine inhibition of receptor activation and downstream signaling pathways. Selected compounds will then be tested for favorable pharmacokinetics (e.g., stability, oral bioavailability, and low BBB penetrance) and pain-reduction in animal models of migraine. The overall goal is to identify a lead compound that can be delivered orally to move into IND-enabling studies for the treatment of migraine pain.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	PARMEDICS, INC	41593 WINCHESTER RD	TEMECULA	CA	92590	RIVERSIDE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	4/2/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	PARMEDICS, INC	41593 WINCHESTER RD	TEMECULA	CA	92590	RIVERSIDE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	5/28/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $310,351 )
2023	2023	PARMEDICS, INC.	41593 WINCHESTER RD STE 228	TEMECULA	CA	92590	RIVERSIDE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	1	2/24/2023	NEW	$0
2023	2023	PARMEDICS, INC.	41593 WINCHESTER RD STE 228	TEMECULA	CA	92590	RIVERSIDE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	1/13/2023	NEW	$310,351
														Subtotal = $310,351

Grand Total All Awards = $310,351

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Protease-activated-receptor-2 antagonists for treatment of migraine pain

Award Number: R41NS127637

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/15/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer